Showing results (21-30 of 151) with videos related to
Sort By:
Pageof 16
Journal of Thoracic Disease|September 16, 2021
The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic reviewXinyu Song, Jiang Fan, Liang Zhu, et al.Plos One|April 27, 2013
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapyFei Zhou, Guanghui Gao, Shengxiang Ren, et al.The Journal of International Medical Research|December 28, 2019
Treatment of spine metastases in cancer: a reviewYu Chen, Yayi He, Chao Zhao, et al.Drug Design, Development and Therapy|May 8, 2018
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLCYayi He, Sangtian Liu, Jane Mattei, et al.Journal of Thoracic Disease|September 21, 2018
Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodulesYayi He, Shengxiang Ren, Yan Wang, et al.Oncotargets and Therapy|November 10, 2018
TIM-3, a promising target for cancer immunotherapyYayi He, Jie Cao, Chao Zhao, et al.Oncotargets and Therapy|August 28, 2018
sLAG-3 in non-small-cell lung cancer patients' serumYayi He, Yan Wang, Sha Zhao, et al.Annals of Translational Medicine|March 12, 2021
Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutationYu Chen, Juan Deng, Yu Liu, et al.Oncotargets and Therapy|October 1, 2019
Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatmentHao Wang, Sha Zhao, Xiaoshen Zhang, et al.Journal for Immunotherapy of Cancer|October 21, 2020
Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancerPeixin Chen, Liping Zhang, Wei Zhang, et al.Pageof 16